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Abstract
Background: Interstitial lung diseases (ILDs) are common in patients with connective tissue diseases (CTDs).
Although the diagnosis of an underlying CTD in ILD (CTD-ILD) affects both prognosis and treatment, it is
sometimes difficult to distinguish CTD-ILD from chronic fibrosing interstitial pneumonia (CFIP). B cell–activating
factor belonging to the tumour necrosis factor family (BAFF) plays a crucial role in B cell development, survival, and
antibody production.
Methods: We examined serum levels of BAFF, surfactant protein D (SP-D), and Krebs von den Lungen-6 (KL-6) in 33
patients with CTD-ILD, 16 patients with undifferentiated CTD-ILD, 19 patients with CFIP, and 26 healthy volunteers.
And we analysed the relationship between serum BAFF levels and pulmonary function, as well as the expression of
BAFF in the lung tissue of patients with CTD-ILD.
Results: Serum levels of BAFF were significantly higher in CTD-ILD patients compared to healthy subjects and CFIP
patients. However, there were no significant differences in serum levels of SP-D and KL-6. Furthermore, serum BAFF
levels in CTD-ILD patients were inversely correlated with pulmonary function. BAFF was strongly expressed in the
lungs of CTD-ILD patients, but weakly in normal lungs.
Discussion: This is the first study to demonstrate that serum BAFF levels were significantly higher in CTD-ILD
patients compared to healthy subjects and CFIP patients. Furthermore, serum BAFF levels were correlated with
pulmonary function. We consider that serum BAFF levels in patients with CTD-ILD reflect the presence of ILDs
disease activity and severity.
Conclusion: These finding suggest that BAFF may be a useful marker for distinguishing CTD-ILD from CFIP.
Keywords: BAFF, Biomarker, CTD-ILD, CFIP
Background
Connective tissue diseases (CTDs) are inflammatory,
immune-mediated disorders that can cause a large var-
iety of pulmonary complications, including bronchiolitis,
pleuritis, and pulmonary hypertension. Interstitial lung
diseases (ILDs) are a common form of pulmonary in-
volvement associated with CTDs that is characterised by
various patterns of inflammation and fibrosis [1].
Interstitial lung involvements of CTD are usually re-
ferred to as interstitial pneumonia, which is further sub-
divided into several histopathological or radiological
entities, including usual interstitial pneumonia (UIP),
nonspecific interstitial pneumonia (NSIP), and organiz-
ing pneumonia (OP).
The prognosis of patients with CTD-ILD is generally
more favourable than those with idiopathic interstitial
pneumonias (IIPs) [1–3]. Some patients with progressive
CTD-ILD may benefit from corticosteroids, immuno-
suppressive therapy, or both [4, 5]. Since a diagnosis of
underlying CTDs affects prognosis and treatment, it is
crucial to evaluate for underlying CTDs in patients with
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ILDs. Although clinical evaluation and measurement of
a variety of autoantibody titres are recommended in the
evaluation for underlying CTDs in patients with ILDs, it
is sometimes difficult to distinguish CTD-ILD from
chronic fibrosing interstitial pneumonia (CFIP), which
including idiopathic pulmonary fibrosis (IPF) and idio-
pathic NSIP [6]. Recent reports have described a popula-
tion of ILDs patients with clinical features of CTDs with
or without autoantibodies who do not meet criteria for a
defined CTDs. This population has been referred to
by several names, including undifferentiated CTD-ILD
(UCTD-ILD), lung dominant CTD, and autoimmune-
featured ILD [1, 7, 8].
Several studies have suggested that serum biomarkers,
such as surfactant protein A (SP-A), surfactant protein
D (SP-D), and Krebs von den Lungen-6 (KL-6), are
useful not only for the diagnosis of ILDs but also for
evaluation of disease activity [6]. However, there are no
studies on whether these biomarkers could be useful for
distinguishing CTD-ILD from CFIP. Markers with higher
specificity may serve as integral components of the evalu-
ation for CTD-ILD.
B cell–activating factor belonging to the tumour
necrosis factor family (BAFF) is responsible for B-cell
survival and maturation [9]. BAFF is expressed by mono-
cytes, macrophages, dendritic cells, and T cells. BAFF en-
codes a putative 285-amino acid type II transmembrane
protein that is biologically active as a cell surface protein
or in a soluble form [10]. BAFF is believed to play a role
in autoantibody production and is considered a promoting
factor in the pathogenesis of several autoimmune diseases
[11]. Elevated serum levels of BAFF have been reported in
patients with systemic lupus erythematosus [12], rheuma-
toid arthritis [13], Sjögren's syndrome [14], systemic scler-
osis [15], and dermatomyositis [16]. Serum BAFF levels
are associated with disease activity for these clinical en-
tities. Furthermore, it has been shown the myositis and
mixed CTD (MCTD) patients with ILDs have significantly
higher BAFF levels than those without ILDs [16, 17]. A
recent study showed plasma BAFF concentrations are
significantly higher in IPF patients than in either COPD
patients or control subjects [18]. However, serum BAFF
levels has never been evaluated in patients with CFIP and
compared with CTD-ILD.
Therefore, we measured serum BAFF levels and evalu-
ated the clinical features of patients with CFIP, UCTD-
ILD, and CTD-ILD, in order to evaluate the utility of
BAFF in detecting CTDs in patients presenting with ILDs.
Methods
Study subjects
Characteristics of ILDs patients enrolled in this study
are shown in Table 1. Sixty-eight patients (35 males and
33 females aged 65.1 ± 9.2 y) were diagnosed with ILDs,
including 19 with CFIP (11 with IPF, 8 with idiopathic
NSIP), 16 with UCTD-ILD, and 33 with CTD-ILD. All
consecutive ILDs patients seen at Kagoshima University
Hospital (Kagoshima, Japan) from 2008 to 2012 were in-
cluded in this study. The diagnosis of CFIP was based
on clinical, radiographic, and pulmonary physiological
Table 1 Characteristics of patients with interstitial lung disease associated with connective tissue disease (CTD-ILD), undifferentiated
CTD-ILD (UCTD-ILD), chronic fibrosing interstitial lung disease (CFIP), and control subjects
Control CFIP UCTD-ILD CTD-ILD p-value
Subjects, n 26 19 16 33
Age, years 64 (59–81) 67 (54–80) 70 (53–79) 63 (39–83) 0.0265
Females, n (%) 16 (61) 3 (15) 8 (50) 22 (66) 0.0032
Smoking status
Former smoker, n (%) 7 (26) 12 (63) 8 (50) 11 (33) 0.0617
Current smoker, n (%) 1 (3) 2 (10) 1 (6) 0 (0) 0.3250
Pack-years 0 (0–40) 30 (0–150) 5 (0–70) 0 (0–100) 0.0035
Pa, O2 mmHg 83.6 (62.4–111.7) 72.5 (58.8–86.6) 79.2 (42.3–105.2) 0.1413
KL-6, U · mL−1 261 (140–491) 1581 (304–8298) 1045 (363–4560) 1117 (289–3943) <0.0001
SP-D, ng · mL−1 32.3 (8.6–126.0) 292.5 (32.3–1070) 206.0 (88.6–405) 175.0 (31.2–994.0) <0.0001
BAFF, ng · mL−1 0.6 (0.5–0.9) 1.0 (0.3–1.9) 1.8 (1.0–2.3) 2.0 (0.6–16.7) <0.0001
VC, L 1.9 (0.9–3.1) 2.1 (0.9–3.1) 2.0 (1.0–3.5) 0.9213
VC, % pred 59.8 (35.4–128.2) 69.2 (37.9–97.4) 65.4 (41.3–104.1) 0.3390
DL,CO, mL · min
−1 · mmHg−1 9.3 (3.4–15.4) 8.9 (4.5–16.9) 10.8 (4.6–16.9) 0.6097
DL,CO, %pred 63.2 (43.5–125.4) 60.4 (26.9–74.4) 64.7 (29.0–109.4) 0.2751
Data are presented as counts (n) or medians and ranges (minimum-to-maximum values), unless otherwise stated. Differences in each variable between the various
groups were analysed using the Kruskal-Wallis test. Pa,O2: oxygen tension in arterial blood; SP-D: surfactant protein D; KL-6: Krebs von den Lungen-6; BAFF: B cell–
activating factor belonging to the tumour necrosis factor family; VC: vital capacity; % pred: % predicted; DL,CO: diffusing capacity of the lung for carbon monoxide
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features, according to the American Thoracic Society/
European Respiratory Society consensus classification
[6, 19]. Histological classification of ILDs was based on
pathologic findings in surgical lung biopsy specimens.
Underlying CTDs consisted of rheumatoid arthritis
(n = 5), dermatomyositis (n = 7), systemic sclerosis (n = 16),
Sjögren's syndrome (n = 1), systemic lupus erythematosus
(n = 1) and MCTD (n = 3). We used American College of
Rheumatology (ACR) criteria for the diagnosis of rheuma-
toid arthritis, systemic sclerosis, Sjögren's syndrome, and
systemic lupus erythematosus. For the diagnosis of
dermatomyositis and MCTD, we used the other criteria
[20, 21]. Patients were considered to have UCTD-ILD if
signs or symptoms or laboratory findings in their medical
record met Kinder’s criteria for UCTD (n = 14) [7]. Pa-
tients with lung cancer, environmental exposures and
other known causes of ILDs were excluded. All serum
samples were collected at the time of diagnosis, prior to
the initiation of systemic steroid or immunosuppressive
therapy, and stored at −80 °C until this investigation.
Twenty-six healthy volunteers with normal chest radio-
graphs not taking any medications were enrolled in our
study as a control group. The Human Ethics Review
Committee of Kagoshima University School of Medicine
approved the study protocol and all participants provided
written informed consent prior to enrolment in the study.
Pulmonary function test
Pulmonary function test, including vital capacity (VC),
forced vital capacity (FVC), and forced expiratory volume
in 1 s was performed using an electrical spirometer. Pre-
dicted FVC values (FVC, % predicted) were calculated.
Diffusing capacity for carbon monoxide (DLCO) was
measured using the single-breath technique or the re-
breathing technique, which was then adjusted to single-
breath values.
Enzyme-linked immunosorbent assay (ELISA)
Serum BAFF was quantified using a sandwich ELISA in
a commercially available kit (Human BAFF ELISA Kit,
R&D Systems, Minneapolis, MN, USA). The lower limit
of detection was 2.43 pg•mL−1. Serum samples with
BAFF levels exceeding the maximum value of the stand-
ard curve for the kit were diluted and re-assayed. Serum
KL-6, SP-D, and SP-A were measured using commercially
available ELISA kits (Eitest KL-6 kit, Sanko Junyaku,
Tokyo, Japan; SP-D kit, YAMASA EIA, Yamasa, Japan;
and SP-A test Kokusai-F kit, International Reagents
Corporation, Kobe, Japan) [22–24].
Immunohistochemical staining of BAFF in lung tissue
We investigated BAFF expression in surgical biopsy
specimens obtained from four never-smoker patients
each with CFIP, UCTD, and CTD-ILD. Normal lung tissue
was obtained from a non-smoker who underwent extirpa-
tion of a postoperative thoracic empyema at Kagoshima
University Hospital. Lung tissue was fixed in 10 % neutral
buffered formalin for 24 to 72 h and embedded in paraffin.
After blocking the endogenous peroxidase activity, depar-
affinised sections (3 μm thick) were pretreated in 1 mM
EDTA buffer (pH 8) and microwaved (600 W) for 8 min.
After cooling for 30 min, the sections were incubated
with goat polyclonal anti-human BAFF/BLyS/TNFSF13B
antibody (R&D Systems) diluted to 1:40 for 30 min
using the DAKO LSAB2 system (DAKO Cytomation,
Glostrup, Denmark). To visualise immunoreactivity,
DAB+ (DAKO Cytomation) was used. Non-immune
serum was used instead of the primary antibody as a
negative control.
Statistical analysis
Since the data were not normally distributed, non-
parametric tests were used for all comparisons. Differ-
ences in each variable between the various groups were
first analysed using the Kruskal-Wallis test, followed by
the Bonferroni test. Fisher's exact test was used to deter-
mine group differences. We considered p values of <0.05
as significant. Statistical analysis was performed using
Graph Pad Prism 6 (Graph Pad, San Diego, CA, USA).
Results
Characteristics of the study participants
Table 1 shows the characteristics of the participants in
the control group and patients with CFIP, UCTD-ILD,
or CTD-ILD. Data are shown as medians and ranges.
Serum BAFF levels in patients with CTD-ILD compared to
patients with CFIP or UCTD and control subjects
Serum levels of BAFF, SP-D and KL-6 are shown in
Fig. 1. Serum KL-6 levels were significantly higher in
patients with CFIP (n = 19; 1581 (304–8298) U•mL−1,
p < 0.0001), UCTD-ILD (n = 16; 1045 (363–4560) U•mL−1,
p = 0.0494), and CTD-ILD (n = 33; 1117 (289–3943)
U•mL−1, p = 0.0069) than in control subjects (n = 26;
261 (140–491) U•mL−1). Similarly, patients with CFIP
(n = 19; 292.5 (32.3-1070) ng•mL−1, p < 0.0001), UCTD-
ILD (n = 16; 206.0 (88.6-405) ng•mL−1, p = 0.0104), and
CTD-ILD (n = 33; 175.0 (31.2-994.0) ng•mL−1, p = 0.0003)
had significantly higher SP-D levels than control subjects
(n = 26; 32.3 (8.6-126.0) ng•mL−1). However, there were
no differences among patients with CTD-ILD, UCTD-
ILD, and CFIP. Conversely, serum BAFF levels were sig-
nificantly higher in patients with CTD-ILD (n = 33; 2.0
(0.6-16.7) ng•mL−1) than in patients with CFIP (n = 19; 1.0
(0.3-1.9) ng•mL−1, p = 0.0074) or healthy controls (n = 26;
0.6 (0.5-0.9) ng•mL−1, p < 0.0001).
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Fig. 1 Distribution of serum a BAFF, (b) SP-D, and (c) KL-6 levels in patients with CTD-ILD (n = 33), undifferentiated CTD-ILD (n = 16), CFIP (n = 19),
and healthy control subjects (n = 26). Differences in each variable across groups were first analyzed using the Kruskal-Wallis test, followed by the
Bonferroni test. BAFF: B cell–activating factor belonging to the tumour necrosis factor family; KL-6: Krebs von den Lungen-6; SP-D: surfactant




Fig. 2 Correlation between serum BAFF, SP-D, and KL-6 levels and pulmonary function testing parameters in patients with CTD-ILD. The
correlation between serum BAFF (a), SP-D (b), and KL-6 (c) and FVC % predicted in CTD-ILD patients is shown. BAFF: B cell–activating factor
belonging to the tumour necrosis factor family; SP-D: surfactant protein D; KL-6: Krebs von den Lungen-6; FVC: forced vital capacity; CTD-ILD:
interstitial lung disease associated with connective tissue disease
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Relationship between BAFF levels and clinical parameters
in patients with CTD-ILD
We analysed the relationship between pulmonary func-
tion testing parameters and markers of interstitial lung
disease (Fig. 2). Serum BAFF levels are inversely correlated
with VC, % predicted (r = −0.40, p < 0.05) in patients with
CTD-ILD. However, there were no significant correlations
between pulmonary function testing parameters and
serum SP-D and KL-6 levels. Sex, smoking status and
serum SP-D and KL-6 were not associated with serum
BAFF levels. There were no significant correlation be-
tween serum BAFF levels and other biomarkers (data were
not shown).
ROC analysis comparing serum BAFF, KL-6, and SP-D
levels between patients with CTD-ILD and CFIP
Compared to control subjects or CFIP patients, serum
BAFF levels were significantly higher in CTD-ILD
patients. We evaluated the sensitivity and specificity of
various serum biomarkers for distinguishing patients
with CTD-ILD from control subjects or CFIP patients
using ROC curve analysis (Table 2). First, the areas
under the ROC curve (AUC) for patients with CTD-ILD
versus controls were 0.972 for serum BAFF, 0.960 for
SP-D, and 0.983 for KL-6. ROC curve analysis showed
that serum BAFF, SP-D and KL-6 levels had good speci-
ficity (BAFF, 95.2 %; SP-D 95.0 %; KL-6, 100 %) and
good sensitivity (BAFF, 91.1 %; SP-D, 94.1 %; KL-6,
94.1 %). We then evaluated the ROC curves for these
markers in patients with CTD-ILD and CFIP. AUC was
highest for BAFF: serum BAFF, 0.832; SP-D, 0.356; and
KL-6, 0.458. The value of BAFF closest to 100 % sensi-
tivity and 100 % specificity selected as the cut-off value
was 1.7 μg•mL−1 (sensitivity, 67 %; specificity, 94 %). Use
of this serum BAFF cut-off level result in a low false-
positive rate for the diagnosis of CTD-ILD among CFIP
patients (5 %, 1/19), however, false-negative in 11 of 33
patients with CTD-ILD. However, no differences were
found in the presence of autoantibodies from individuals
with below or above the cut-off level. Overall, using
serum BAFF in the diagnosis of CTD-ILD yielded the
highest diagnostic accuracy and the greatest sensitivity,
specificity, and likelihood ratio among these markers.
These results demonstrate that patients with CTD-ILD
can be distinguished from controls or CFIP patients
using measurements of serum BAFF levels.
Immunohistochemical staining for BAFF
Figure 3 shows representative BAFF immunohistochemi-
cal staining of lung specimens obtained from patients
with CTD-ILD and normal areas of lungs surgically re-
moved to treat thoracic empyema. In lung specimens
from patients with CTD-ILD, BAFF was clearly overex-
pressed, mainly in alveolar macrophages in the airspace
and infiltrating lymphoid cells, including those arranged
in follicular patterns. BAFF positivity was also detected
in the cytoplasm of the epithelial cells of the peripheral
airways, endothelial cells in blood vessels and fibroblasts
(Fig. 3b-g). BAFF was expressed weakly in normal lung
tissues (Fig. 3a), which considered as non-specific stain-
ing compared with polyclonal goat IgG control (Fig. 3b).
There were no clear differences in the expression of
BAFF in lung specimen from patients with CTD-ILD
versus CFIP (Fig. 3h,-i).
Discussion
We demonstrated that serum BAFF levels in patients
with CTD-ILD were significantly higher than in patients
with CFIP and healthy controls. Immunohistochemically,
lung sections from patients with CTD-ILD are strongly
positive for BAFF in cells of the alveolar walls, peripheral
airways, and lymphoid follicles. Moreover, there was a
significant correlation between serum BAFF levels and
disease severity in patients with CTD-ILD.
Several biomarkers for the diagnosis of ILDs have been
found. SP-D and KL-6 levels have been shown to be
higher in all of major types of CFIP. One study found
serum SP-A and SP-D levels were significantly higher in
IPF compared to NSIP/cryptogenic OP or CTD-ILD [25,
26]. However, the specificity of these biomarkers has not
been evaluated for CTD-ILD, UCTD, lung dominant
CTD, and autoimmune-featured ILD. In the present
study, serum SP-D and KL-6 levels in patients with
CTD-ILD were similar to those in CFIP patients, and
there was no relationship observed between serum SP-D
or KL-6 levels and disease activity. Conversely, BAFF
was specific for CTD-ILD, and we expect it could be a
useful clinical biomarker for distinguishing CTD-ILD
from CFIP.
Table 2 ROC analysis comparing serum BAFF, KL-6, and SP-D levels between patients with CTD-ILD and CFIP
AUC Cut-off value Sensitivity, % (95 % CI) Specificity, % (95 % CI) Likelihood ratio
BAFF 0.823 1.7 ng · mL−1 67.6 (49.4 to 82.6) 94.7 (73.9 to 99.8) 12.85
KL-6 0.566 1562 U · mL−1 79.4 (62.1 to 91.3) 52.6 (28.8 to 75.5) 1.67
SP-D 0.643 158 ng · mL−1 47.1 (29.7 to 64.8) 77.7 (52.3 to 93.5) 2.11
BAFF: B cell–activating factor belonging to the tumour necrosis factor family; SP-D: surfactant protein D; KL-6: Krebs von den Lungen-6; CTD-ILD: interstitial lung
disease associated with connective tissue disease; CFIP: chronic fibrosing interstitial lung disease; ROC: receiver operating characteristic; AUC: area under the ROC
curve; CI: Confidence interval
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For patients with ILDs, current guidelines recommend
an evaluation for underlying CTD. This evaluation will
yield a subset of ILD patients with symptoms and auto-
antibodies suggestive of an autoimmune condition who
do not fulfil ACR criteria for CTDs. These patients, in
whom the lung is the only or most clinically important
manifestation of occult CTDs, are suspected of having a
systemic autoimmune disease due to the presence of
circulating autoantibodies, specific histopathological
features on surgical lung biopsy samples, or subtle extra-
thoracic manifestations. They could be possibly be clas-
sified as having a subtype of CTD-ILD rather than CFIP
[27]. The proposed terminology for such patients in-
cludes undifferentiated CTD-ILD [7], lung-dominant
CTD [27], and autoimmune-featured ILD [8]. Strategies
for identifying and diagnosing these patients are contro-
versial and confusing. One reason is that multiple
specific autoantibodies are needed for diagnosing UCTD
since it includes multiple autoimmune diseases. Our
findings show that patients who met Kinder’s criteria for
UCTD had significantly higher serum BAFF levels than
patients with CFIP; however, the levels of SP-D and
KL-6 in patients with UCTD and CFIP were similar.
We presume that serum BAFF levels in patients with
UCTD-ILD might be higher than in patients with
CFIP, and these patients would be classified as having
CTD-ILD or a possible subtype of CTD-ILD based on
high serum BAFF levels. Previous study showed plasma
BAFF concentrations are significantly higher in IPF pa-
tients than in control subjects [18]. However, our present
study showed serum BAFF levels are significantly higher
in CTD-ILD patients than in CFIP patients (which include
IPF and idiopathic NSIP). In addition, high serum BAFF
levels in ILDs patients may guide initial therapy and
Fig. 3 Representative immunohistochemical findings for BAFF in lung sections. Tissue was obtained from a, b a 23-year-old female non-smoker
as a control, (c–g) a 56-year-old female non-smoking patient with CTD-ILD, and (h, i) a 63-year-old male non-smoking patients with CFIP. Weakly
positive alveolar macrophages were observed in the a) BAFF b) goat IgG control. Strong cytoplasmic positivity of BAFF was observed in c), h)
peripheral airways macrophages and cells in the alveolar walls, d), i) lymphoid follicles, e) peripheral airways, f) vascular endothelial cell and
g) fibroblasts. Scale bars = 50 μm. BAFF: B cell–activating factor belonging to the tumour necrosis factor family; CTD-ILD: interstitial lung disease
associated with connective tissue disease; CFIP: chronic fibrosing interstitial lung disease
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prognosis, since treatment improves survival in patients
with CTD-ILD compared to those with idiopathic ILDs
[11]. NSIP is the most common histological finding in pa-
tients with CTD-ILD who meet established ACR criteria,
and CTD-ILD is often accompanied by fibrotic interstitial
pneumonia that resembles IIPs [11]. Additionally, it has
been shown that most patients diagnosed with idiopathic
NSIP meet the UCTD of Kinder et al. [7]. The distinction
between idiopathic NSIP and IPF has important prognos-
tic and treatment implication [28]. However, histologically
distinguishing NSIP with CTD-ILD from NSIP with CFIP
is difficult. There are reports that 10 % and 52 % of
patients who were considered to have idiopathic NSIP
developed CTDs during follow-up [29, 30]. In addition to
various specific autoantibody titres, serum BAFF levels
might be helpful for distinguishing CTD-ILD and UCTD
from CFIP.
This is the first study to demonstrate that patients
with CTD-ILD have significantly higher serum BAFF
levels than patients with CFIP and healthy controls, as
well as significant correlations between serum BAFF
levels and parameters indicating disease severity such as
VC, % predicted and DLCO, % predicted. BAFF immuno-
reactivity was detected in alveolar macrophages and in-
filtrating lymphoid cells in patients with COPD in a
prior study [31]. In this study, we found overexpression
of BAFF in patients with CTD-ILD, mainly in alveolar
macrophages in the air space, parenchymal lymphoid
follicles, fibroblasts and alveolar walls. Previous studies
have found increased serum levels of BAFF in a subset
of patients with idiopathic inflammatory myopathies or
MCTD [16, 17] compared to healthy individuals, and
that patients with ILDs had higher BAFF levels than
patients without ILDs. Taken together, we consider that
serum BAFF levels in patients with CTD-ILD and
UCTD reflect the presence of ILDs activity and severity.
Belimumab is a purely human monoclonal antibody
that targets BAFF. It has been used for the first targeted
biological treatment approved specifically for systemic
lupus erythematosus [32]. Our findings suggest that
BAFF might be a new potential target for therapy in pa-
tients with CTD-ILD and UCTD-ILD.
Our study has several limitations. First, our study was
retrospective in nature. Second, our sample size was lim-
ited and our results represent the experience of only a
single centre. Therefore, a multicentre study with a lar-
ger cohort will be required to confirm our results. We
will also need to clarify the relationship between these
biomarkers and histological patterns of CTD-ILD and
possible subtypes of CTD-ILD.
Conclusions
In summary, increased levels of BAFF were found in the
circulation of patients with CTD-ILD and UCTD-ILD, in
whom serum levels were inversely correlated with lung
function. Immunohistochemical studies showed BAFF
overexpression in the lung parenchyma in CTD-ILD. Our
findings suggest that serum BAFF levels may be clinically
useful for distinguishing CTD-ILD from CFIP.
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